Product Specifications Biotin-IGF-I, human:

Biotin- IGF-I is prepared by a selective biotinylation procedure, that ensures full binding capacity to IGF-binding proteins-1 to -5. As in natural IGF-I, binding to IGFBP-6 is strongly reduced. Binding to antiserum PAA is not affected.

Examples of applications of biotinylated IGF's can be seen in application note 4.

Formulation: Lyophilised from a solution of  0.5 ml TBS, pH 7.4, containing 10 µg of the biotinylated product . A  preservative and a stabilising protein of non-mammalian origin are added to ensure stability of the reconstituted product.

Recommended dilution: 1: 100 to 1: 250 for western ligand blotting. Tested with our western-ligand blotting kit, in ELISA, in cross-linking experiments, in IHC and binding studies. The use of biotinylated IGF-I in experimental celltheraphy has demonstrated, that it is biologically active in-vitro and in vivo.

Storage: Store refrigerated upon arrival. The product is stable at 4 °C for
at least one year.  Reconstitute with 0.5 ml water and store aliquots frozen at - 20 °C. Avoid repeated freeze-thawing cycles.
References:
1.) Michael E. Davis*, Patrick C. H. Hsieh*, Tomosaburo Takahashi*, Qing Song, Shuguang Zhang, Roger D. Kamm, Alan J. Grodzinsky, Piero Anversa, and Richard T. Lee*: Local myocardial insulin-like growth factor 1 (IGF-1) delivery with biotinylated peptide nanofibers improves cell therapy for myocardial infarction. PNAS | May 23, 2006 | vol. 103 | no. 21 | 8155-8160
Link to article:

www.pnas.org/cgi/content/full/103/21/8155

2.) Altmann et. al.: The relationships between leptin concentrations and body fat reserves in lambs are reduced by short-term fasting.Journal of Animal Physiology and Animal Nutrition 2006, Vol. 90, issue 9-10, p407 - 413.

Link to article:

http://www.biomedcentral.com/1471-2407/10/320

3.) Bolos et al.: ORAL ADMINISTRATION OF A GSK3 INHIBITOR INCREASES BRAIN INSULIN-LIKE GROWTH FACTOR-I LEVELS. JBC Papers in Press. Published on March 29, 2010.
http://www.jbc.org/content/early/2010/03/29/jbc.M109.096594.full.pdf.

4.) Nishijima et al.: Neuronal Activity Drives Localized Blood-Brain-Barrier Transport of Serum Insulin-like Growth Factor-I into the CNS. Neuron 67, 834–846, September 9, 2010.

Link to Article:

http://digital.csic.es/bitstream/10261/27623/1/NeuronCSICRepository.pdf

Rev. 2013-02

about://journal/118623803/issue

 Datasheet for Human IGF-I, Biotinylated (Biotin-IGF-I, human)